Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2019 Jan;26(1):4-9.
doi: 10.1136/ejhpharm-2017-001258. Epub 2017 Sep 20.

Adherence and preference of intravenous zoledronic acid for osteoporosis versus other bisphosphonates

Maria José Fobelo Lozano  1 , Susana Sánchez-Fidalgo  1   2
Affiliations
Review

Adherence and preference of intravenous zoledronic acid for osteoporosis versus other bisphosphonates

Maria José Fobelo Lozano et al. Eur J Hosp Pharm. 2019 Jan.

Abstract

Objective: To evaluate adherence as well as patient preference and satisfaction of once-yearly intravenous zoledronic acid versus other bisphosphonates treatments.

Methods: In accordance with the PRISMA guidelines, a systematic literature search was conducted in PubMed, Cochrane Library and EMBASE databases, over the date range of 2000-2016. Following the PICO (Population, Interventions, Comparator, Outcomes) elements, eligibility criteria included: (1) participants: adults over 18 with osteoporosis and adults who were at high risk of developing low bone density as a result of chronic use of glucocorticoids; (2) intervention: adherence or patient preference/satisfaction of once-yearly zoledronic acid treatment; (3) comparator: other bisphosphonates; (4) outcome: data about adherence, persistence, compliance, preference and satisfaction criteria. Specific exclusion criteria were also applied.

Results: Adherence to zoledronate is only quantified in one study showing that mean proportion of days covered for zoledronic acid was greater than for ibandronate users. Three studies showed 100% of compliance to zoledronate treatment and only one study showed zoledronic acid provided the highest persistence rates. Once-yearly intravenous infusion of zoledronic acid was clearly preferred. Only one article indicated preference for schedules that were once monthly or less frequent and other preference results practically equal between once-yearly intravenous infusion or weekly oral. Although there is little evidence, adherence to osteoporosis treatment is improved with annual intravenous zoledronate regimen. Moreover, patients appear to have preference for less frequent dosing. Switching from oral to intravenous therapy, based on the opportunities offered by an integrated health management area, may allow obtaining better outcomes in adherence to osteoporosis treatment.

Keywords: adherence; osteoporosis; preference; satisfaction; zoledronic acid.

PubMed Disclaimer

Conflict of interest statement

Competing interests: None declared.

Figures

Figure 1
Figure 1
Study flow diagram.
See this image and copyright information in PMC

References

    1. McElnay JC, McCallion CR, al-Deagi F, et al. . Self-reported medication non-compliance in the elderly. Eur J Clin Pharmacol 1997;53:171–8. 10.1007/s002280050358 - DOI - PubMed
    1. Larrea P V, Mir M I. Adherencia al tratamiento en el paciente anciano. Inf Ter Sist Nac Salud 2004;28:113–20.
    1. McDonald HP, Garg AX, Haynes RB. Interventions to enhance patient adherence to medication prescriptions: scientific review. JAMA 2002;288:2868–70. 10.1001/jama.288.22.2868 - DOI - PubMed
    1. Sabaté E. Adherence to long-term therapies: evidence for action. Geneva: World Health Organization 2003;194.
    1. Osterberg L, Blaschke T. Adherence to medications. N Engl J Med Overseas Ed 2005;353:487–97. 10.1056/NEJMra050100 - DOI - PubMed